KLHL5 activators are a specialized group of compounds that target the regulation of the Kelch-like family member 5 (KLHL5) protein. KLHL5 is a part of the BTB-Kelch superfamily, which is known for its involvement in various cellular mechanisms through protein-protein interactions. The proteins in this family typically contain a BTB (Broad-Complex, Tramtrack, and Bric-a-brac) domain, which mediates the interaction with Cullin3, a core component of E3 ubiquitin ligase complexes, and multiple Kelch motifs that are responsible for substrate recognition. The activators of KLHL5 are designed to modulate the activity of this protein, potentially affecting its role in the ubiquitination process where proteins are tagged for degradation or functional modification. The exact molecular action of these activators may involve increasing the protein's stability, enhancing its affinity for specific substrates, or facilitating the assembly of the E3 ligase complex in which KLHL5 participates.
The development of KLHL5 activators necessitates a comprehensive exploration of the protein's structure and the elucidation of its interaction networks within the cell. Once such sites are determined, activators can be synthesized and optimized for better interaction with the protein. These compounds are often characterized by their ability to bind selectively and with high affinity to KLHL5, influencing its conformation and activity in a manner that promotes its physiological function. In addition, the chemical properties of these activators, such as solubility, stability, and cell permeability, are fine-tuned to ensure that they can effectively reach and act on KLHL5 within the complex cellular environment.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
A modulator of the ubiquitin ligase complex, known for its teratogenic effects, but also studied for its influence on the protein homeostasis system, which could affect KLHL5. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
A lactacystin-derived compound that irreversibly inhibits proteasome activity, altering protein turnover and possibly impacting KLHL5 activity indirectly. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
A selective inhibitor of the deubiquitinating enzyme USP14, which can enhance the degradation of proteins by the proteasome and might affect substrates relevant to KLHL5. | ||||||
NMS-873 | 1418013-75-8 | sc-478803 | 5 mg | $300.00 | ||
An inhibitor of ubiquitin-specific protease 7 (USP7), potentially altering the deubiquitination process and indirectly influencing KLHL5-related pathways. | ||||||